Evidence map›Paper›PMID 37377240›Full record

ArticleRevista peruana de medicina experimental y salud publica

Medication use in pediatric patients with covid-19 hospitalized in a referral hospital in Lima, Peru, 2020 - 2022.

Medalit Luna-Vilchez, Jhonatan R Mejia, Zhamanda N Ortiz-Benique, Mitsi Santiago-Abal, Alvaro Taype-Rondan

Open access · diamondAbstract read
In one paragraph

Article in Revista peruana de medicina experimental y salud publica. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Medalit Luna-VilchezInstituto Nacional de Salud del Niño San Borja, Lima, Perú.ORCID http://orcid.org/0000-0003-3351-7877
Jhonatan R MejiaUniversidad Científica del Sur, Lima, Perú.ORCID http://orcid.org/0000-0002-9846-8503
Zhamanda N Ortiz-BeniqueFacultad de Medicina, Universidad Nacional de San Agustín de Arequipa, Arequipa, Perú.ORCID http://orcid.org/0000-0001-6608-0179
Mitsi Santiago-AbalInstituto Nacional de Salud del Niño San Borja, Lima, Perú.ORCID http://orcid.org/0000-0001-6457-2508
Alvaro Taype-RondanEviSalud - Evidencias en Salud, Lima, Perú.ORCID http://orcid.org/0000-0001-8758-0463
Instituto Nacional de Salud del Niño · PEUniversidad Científica del Sur · PEUniversidad Nacional de San Agustin de Arequipa · PEUniversidad San Ignacio de Loyola · PE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation for the study. Therapeutic guidelines for COVID-19 in children changed constantly during the pandemic. In Peru, the variation of the treatment during the different waves of the pandemic has not been studied. Main findings. During the third wave, there was a greater number of patients with COVID-19; however, these patients had less severe symptoms. The use of ceftriaxone and azithromycin was less frequent during the third wave. The use of immunoglobulin was only found in patients with pediatric inflammatory multisystemic syndrome. Implications. Determining the patterns of medication use during the COVID-19 pandemic in the pediatric population will allow us to evaluate how the therapeutic decision-making process evolved in this population.

Indexed as

COVID-19AzithromycinChildHospitalsHumansPandemicsPeruAzithromycin

Identifiers

PMID37377240
PMCPMC10959514
OpenAlexW4366818088

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.